The migraine market consists of a multitude of therapies that either acutely treat migraine attacks or serve as prophylactic treatment. Among acute antimigraine therapies, triptans and NSAIDs/…
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…
The acute migraine market is dominated by the oral triptans, although genericization of these agents as well as approvals in recent years of multiple non-oral triptans and non-triptans have begun…
From disease basics to insightful analysis of market dynamics, Glioma | Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing critical aspects of the…
The type 2 diabetes therapy market will rapidly expand over our 2015-2025 study period, fueled by the disease’s increasing prevalence and a high unmet need for drugs that can effectively control…
The uptake of biosimilar erythropoiesis-stimulating agents (ESAs) varies from country to country, as well as by drug and manufacturer. European nephrologists have been able to prescribe ESAs to…
Pancreatic cancer remains a deadly disease with limited treatment options. The current standards of treatment are mFOLFIRINOX and gemcitabine + Abraxane. Market growth over the forecast period to…
The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral agents, particularly the latest single-tablet regimens (STRs) with improved side-effect profiles…
The Current Treatment Bone and Mineral Metabolism (BMM) disorders content examines the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of…
The systemic lupus erythematosus (SLE) market in the United States is largely genericized and off-label. With the exception of Benlysta (IV)—which launched in 2011—no new drug has been approved…
The Current Treatment Bone and Mineral Metabolism (BMM) disorders content examines the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of…
Although TNF-α inhibitors revolutionized the treatment landscape for moderate to severe Crohn’s disease (CD), considerable unmet need remains. For instance, a notable percentage of patients do…
Five TNF-α inhibitors and four biologics with alternative mechanisms of action are currently approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Germany, Italy, Spain,…
Type 2 diabetes (T2D) is a complex metabolic disorder characterized by a declining ability to produce or utilize insulin. The chronic and progressive nature of the disease, as well as its…
This detailed, expanded analysis explores key access and reimbursement topics in the rare disease space in the United States, such as the approaches managed care organizations take to control both…
